Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias EJ, Bartz H, Taut FJH, Reich K. Eyerich K, et al. Among authors: weisenseel p. BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822. BMJ Open. 2021. PMID: 34518264 Free PMC article.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: weisenseel p. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
[Inverse psoriasis].
Weisenseel P, Reich K. Weisenseel P, et al. Hautarzt. 2015 Jun;66(6):408-12. doi: 10.1007/s00105-015-3628-7. Hautarzt. 2015. PMID: 25896586 Review. German.
[Pustular psoriasis].
Weisenseel P, Wilsmann-Theis D, Kahl C, Reich K, Mössner R. Weisenseel P, et al. Hautarzt. 2016 Jun;67(6):445-53. doi: 10.1007/s00105-016-3804-4. Hautarzt. 2016. PMID: 27240667 Review. German.
Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis.
Reich K, Deinzer J, Fiege AK, von Gruben V, Sack AL, Thraen A, Weisenseel P, Breuer K, Jäckle S, Meier M. Reich K, et al. Among authors: weisenseel p. J Allergy Clin Immunol. 2016 Jun;137(6):1882-1884.e6. doi: 10.1016/j.jaci.2016.01.016. Epub 2016 Mar 15. J Allergy Clin Immunol. 2016. PMID: 26993034 Free article. Clinical Trial. No abstract available.
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Menter A, Arenberger P, Balser S, Beissert S, Cauthen A, Czeloth N, Soung J, Jazayeri S, Weisenseel P, Jayadeva G. Menter A, et al. Among authors: weisenseel p. Expert Opin Biol Ther. 2021 Jan;21(1):87-96. doi: 10.1080/14712598.2021.1851362. Epub 2020 Dec 29. Expert Opin Biol Ther. 2021. PMID: 33317345 Free article. Clinical Trial.
39 results